Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma

Trial Profile

Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Carmustine polifeprosan 20 wafer (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 12 Sep 2017 Discrepancy was found in the trial status from NCT and Japic registry. As per NCT this trial was completed and as per Japic it is active no longer recruiting. I have sent mail to the investigator for the confirmation and waiting for the reply (_ML_CLNCL@hhc.eisai.co.jp).
    • 11 Sep 2017 Planned End Date changed from 1 Feb 2017 to 31 Mar 2017.
    • 18 Apr 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top